1. Significance of LL-37 on Immunomodulation and Disease Outcome
- Author
-
Zhengjun Yi, Guoying Ni, Tamim Mosaiab, Ming Q. Wei, Lu Yang, Rushdi Fadhil, Jasmine Kaur, David Good, Wei Liu, Calvin Jessop, Binbin Yang, and Xiaosong Liu
- Subjects
Disease outcome ,medicine.medical_treatment ,Antineoplastic Agents ,Inflammation ,Review Article ,Biology ,medicine.disease_cause ,General Biochemistry, Genetics and Molecular Biology ,Cathelicidin ,Immunomodulation ,Mice ,Immune system ,Anti-Infective Agents ,Cathelicidins ,Neoplasms ,Small peptide ,medicine ,Animals ,Humans ,Psoriasis ,Biological sciences ,General Immunology and Microbiology ,Chemotaxis ,Immune regulation ,General Medicine ,Inflammatory Bowel Diseases ,Immunology ,Medicine ,medicine.symptom ,Carcinogenesis ,Antimicrobial Cationic Peptides - Abstract
LL-37, also called cathelicidin, is an important part of the human immune system, which can resist various pathogens. A plethora of experiments have demonstrated that it has the multifunctional effects of immune regulation, in addition to antimicrobial activity. Recently, there have been increasing interest in its immune function. It was found that LL-37 can have two distinct functions in different tissues and different microenvironments. Thus, it is necessary to investigate LL-37 immune functions from the two sides of the same coin. On the one side, LL-37 promotes inflammation and immune response and exerts its anti-infective and antitumor effects; on the other side, it has the ability to inhibit inflammation and promote carcinogenesis. This review presents a brief summary of its expression, structure, and immunomodulatory effects as well as brief discussions on the role of this small peptide as a key factor in the development and treatment of various inflammation-related diseases and cancers.
- Published
- 2020
- Full Text
- View/download PDF